TERAZOSIN EVALUATION AS MALE LUTS TREATMENT USING IPSS SUB-SCORING RATIO

1Christian Ronald K. Tanggo, 1Ferry Safriadi.

1Department of Urology, Faculty of Medicine/Padjadjaran University, Hasan Sadikin Hospital, Bandung, Indonesia.

ABSTRACT

Objective: To evaluate the improvement of Lower Urinary Tract Symptoms (LUTS) in males treated with terazosin based on sub scoring ratio of the International Prostate Symptom Score (IPSS). Material & Method: Sixty eight male with LUTS subjected to terazosin 1 mg daily and divided into two groups based on IPSS sub scoring ratio. After 3 months improvement of the symptoms were evaluated using the IPSS. Data analysis was done using paired T-test. The conclusion was based on significance level p < 0,05. Results: The IPSS score was improving on both failure to void group (IPSS- v/s >1) and failure to store group (IPSS- v/s ≤1) after 3 months of Terazosin therapy (mean = 9.56 versus 6.94). Statistically superior improvement was observed on failure to voiding group (p = 0,0003) (95CI : 1.30-3.93). Conclusion: Terazosin is best given to male LUTS with IPSS- v/s > 1 although both groups respond well.

Keywords: International prostate symptom score, sub score, failure to voiding, failure to storage, male, lower urinary tract symptoms.

INTRODUCTION

Alpha adrenoceptor antagonist therapy in men with Lower Urinary Tract Symptoms (LUTS) who were diagnosed with benign prostate enlargement or Benign Prostatic Hyperplasia (BPH) is still a problem. 1 Most guidelines refer to alpha adrenoceptor antagonist as the first line medical treatment in male LUTS. It is an evidence that not all patient showed a favorable response both voiding and storage symptoms to the therapy. 2-6 Recent studies confirm LUTS not only produced by lower urinary tract obstruction but also failure of the bladder detrusor muscle. 7-8 There is a shifting paradigm to start focus on the bladder pathology rather than the prostate alone. 6-11 Multiple studies already demonstrate the contribution of bladder dysfunction to male LUTS, and examine the relationship between symptoms and urodynamic findings. 11-16

Liao et al (2011) introduced a sub scoring ratio system in IPSS to differentiate voiding or
storage symptoms as the more prominent symptoms responsible in the IPSS. We assess the symptoms improvement on male with LUTS whom given terazosin based on sub scoring ratio system.

**OBJECTIVE**

To evaluate the improvement of male with LUTS treated by terazosin based on sub scoring ratio of the IPSS.

**MATERIAL & METHOD**

Sixty eight males with LUTS were enrolled within March until May 2011 in Hasan Sadikin hospital, Bandung, Indonesia. Men older than 50 years old with LUTS and without urinary tract infection, bladder stone or cancer, history of urinary retention and neurovascular disease were included. They were divided into failure of storage (v/s <2) and failure of voiding (v/s > 1) groups based on IPSS v/s sub score ratio system. Both groups were given 1 mg of terazosin daily, which is the therapeutic dose in Indonesia. The symptoms and uroflowmetry results were recorded before and after 1, 2, and 3 months of terazosin therapy. Statistical comparisons between the groups were tested using paired T-test. The conclusion was based on significance level p<0.05.

**RESULTS**

The mean age was 66 years (range, 54-81 years). Table 1 shows total IPSS and maximum flow rate (Qmax) of uroflowmetry on both groups before and after terazosin therapy. The mean IPSS score of failure to voiding group is 15,00 and failure to storage group is 15,03 (n1 = n2 = 34) before therapy. The Qmax is 6,79 cc/sec on failure to voiding group and 6,94 cc/sec on failure to storage group. The mean IPSS score after 1, 2, and 3 months therapy are 8,97; 6,97; and 5,44 on failure to voiding group and 11,56, 9,41; 8,08 on failure to storage group. The Qmax after therapy is 10,50 and 10,41 on failure to voiding and storage groups respectively. Table 2 shows IPSS improvement on both groups after 1st, 2nd and 3rd months of therapy (6,03; 8,09; 9,56 and 3,47; 5,62; 6,95; failure to voding and storage groups, respectively). The difference only in the 3rd month is statistically significant (p = 0,0003) (95CI : 1,30-3,93). Table 3 shows Qmax improvement on both groups after 3 months of therapy (3,71 and 3,47; failure to voding and storage groups, respectively) but the difference between both groups is not significant.

**DISCUSSION**

Lower urinary tract symptoms are common in aging male. Many tools have been advocated for the therapeutic purposes including urodynamic study. IPSS sub scoring ratio system proposed by Liao is one of these tools especially when urodynamic study is unavailable.

In this study, we evaluated the symptoms improvement after terazosin therapy on male with LUTS based on sub scoring ratio system and we found better improvement on failure to voiding group.

| Table 1. Total IPSS Score and Qmax before and after 3 months of terazosin therapy. |
|-----------------|-----------------|-----------------|-----------------|
| Before terazosin therapy | After terazosin therapy | Qmax |
| **Total IPSS** | **Qmax** | **Total IPSS (month of therapy)** | **Qmax** | **Total IPSS** | **Qmax** | **Total IPSS (month of therapy)** | **Qmax** |
| Failure to voiding | 15 | 6,79 | 8,97 | 6,91 | 5,44 | 10,5 |
| Failure to storage | 15,03 | 6,94 | 11,56 | 9,41 | 8,08 | 10,41 |
| Total | 15,01 | 6,87 | 10,26 | 8,16 | 6,76 | 10,46 |
CONCLUSION

We found that terazosin is best given to male LUTS with IPSS- v/s >1 although both groups respond well.

REFERENCES

1. Wei JT, Calhoun E, Jacobsen SJ. Urologic disease in America project: Benign prostate hyperplasia. J Urol. 2005; 173: 1256-61.
2. Naslund MJ, Gilsenan AW, Midkiff KD. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007; 61(9): 1437-45.
3. De la Rosette JJ, Witjes WP. Relationship between lower urinary tract symptoms and bladder outlet obstruction. Neurol. Urodyn. 1998; 17(2): 99-108.
4. Chapple C, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: Focus on bladder. Eur Urol. 2006; 49(4): 651-8.
5. Roehrborn CG. Benign prostate hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 2584-5.
6. Liao CH, Chung SD, Kuo HC. Diagnostic value of international prostate symptom score voiding-storage subscore ratio in male lower urinary tract symptoms. Int J Clin Pract. 2011; 65(5): 552-8.
7. Wein AJ. Pathophysiology and classification of lower urinary tract dysfunction: Overview. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 1834-46.
8. Roehrborn CG. Clinical management of lower urinary tract symptoms with combined medical therapy. BJU Int. 2008; supp 2: 13-7.
9. Djavan B, Marberger M. A meta-analysis of the efficacy and tolerability of alfa-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999; 36: 1-13.
10. Barkin J, Guimaraes M. Alfa blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol. 2003; 44: 461-66.
11. Michel MC, Vrydag W. α1-, α2- and β-adrenoceptor in the urinary bladder, urethra and prostate. BJ Pharm. 2006; 147: 88-119.
12. Djavan B, Chapple C, Milani S. State of the art of the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Urol; 64. p. 1081-8.
13. Hillman AL, Schwartz JS, Willian MK. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urol. 1996; 47(2): 169-78.
14. Abrams P, Chapple C, Khoury S. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009; 181(4): 1779-87.
15. McNicholas T, Kirby R. Evaluation and nonsurgical management of benign prostate hyperplasia. Campbell-Walsh Urology. 10th ed. Philadelphia: WB Saunders; 2011. p. 2611-53.